- Chronic Myeloid Leukemia (CML) predominantly affects adults aged 50 to 55; in 2017, over 12,000 patients in Brazil received outpatient treatment approval for CML despite the lack of reimbursements for necessary monitoring tests like quantitative PCR.
- Effective monitoring through molecular response evaluation is vital for optimal CML patient care, enabling timely interventions and even possible treatment discontinuation for suitable cases.
- Expert recommendations emphasize the urgent need for funding and reimbursement for molecular testing in SUS, highlighting potential cost savings from reduced medication usage when patients are closely monitored.